IVRO (Invitro International) Total Liabilities: $0.30 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Invitro International Total Liabilities?

Invitro International IVRO Total Liabilities is $0.30 Mil as of Jun. 2026. The stock has 1 warning sign investors should review.

Invitro International's Total Liabilities for the quarter that ended in Jun. 2026 was $0.30 Mil.

Invitro International's quarterly Total Liabilities declined from Dec. 2025 ($0.32 Mil) to Mar. 2026 ($0.31 Mil) and declined from Mar. 2026 ($0.31 Mil) to Jun. 2026 ($0.30 Mil).

Invitro International's annual Total Liabilities increased from . 20 ($0.00 Mil) to Sep. 2024 ($0.38 Mil) but then declined from Sep. 2024 ($0.38 Mil) to Sep. 2025 ($0.35 Mil).


Invitro International Total Liabilities Historical Data

* Premium members only.

The historical data trend for Invitro International's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invitro International Total Liabilities Chart

Invitro International Annual Data
Trend Sep24 Sep25
Total Liabilities
0.38 0.35

Invitro International Quarterly Data
Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only 0.35 0.35 0.32 0.31 0.30

Invitro International Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Invitro International's Total Liabilities for the fiscal year that ended in Sep. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.124273+(0+2.7755575615629E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+++)
=0.12

Total Liabilities=Total Assets (A: Sep. 2025 )-Total Equity (A: Sep. 2025 )
=2.002889-1.65471
=0.35

Invitro International's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=1.998007-1.696626
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.30 Mil mean?
Invitro International (IVRO) has a Total Liabilities of $0.30 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Invitro International and its competitors.
Is Invitro International's Total Liabilities too high?
Invitro International's current Total Liabilities is $0.30 Mil.
How does Invitro International's Total Liabilities compare to IDTA and FUNI?
Invitro International's Total Liabilities of $0.30 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Invitro International and its competitors. Invitro International's current Total Liabilities is $0.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invitro International stock overvalued right now?
Based on GuruFocus' analysis, Invitro International (IVRO) is currently considered Fairly Valued. The stock's GF Value™ is $0.06, compared to a current price of $0.06 — trading right at its estimated fair value. The current Total Liabilities is $0.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Invitro International (IVRO), the current Total Liabilities is $0.30 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invitro International Business Description

Address 330 East Orangethorpe Avenue, Suite D, Placentia, CA, USA, 92870
Invitro International is a provider of non-animal testing methods. The company develops and commercializes test kits and laboratory services. Its testing technologies are designed to produce data regarding corrosivity, or ocular/dermal irritation, which correlate with animal and human test results. Its products and services include Irritection, Corrositex, and Lab Services. The company provides its products to various industries such as cosmetics, personal care, household products, textiles, pharmaceuticals, chemicals, and hazardous waste transportation. The majority of its revenue is generated from the United States and it also exports to other countries.